文献速递临床生化临床免疫质量管理与危急值

基于液相色谱-串联质谱再校准降低醛固酮检测的跨平台差异

Liquid chromatography-tandem mass spectrometry-based recalibration reduces inter-platform variability in aldosterone detection across chemiluminescence immunoassay platforms.
PubMed 文献 · Clin Chim Acta · 2025-10-14

LC-MS/MS测得醛固酮显著低于6个CLIA平台,再校准可显著降低相对平均差异,但对比例偏差和系统偏差改善有限。

要点

  • LC-MS/MS测得的醛固酮水平显著低于6个CLIA平台。
  • 各检测方法相关性很强,但回归斜率多偏离1,平台间相对平均差异较大。
  • 以LC-MS/MS为参照再校准可降低相对平均差异,但比例与系统偏差改善有限。

核心结论

  • 6个CLIA平台与LC-MS/MS检测醛固酮的一致性不理想,基于LC-MS/MS的再校准可降低相对平均差异,但残留的比例偏差和系统偏差提示需优化校准策略与检测方法。

研究设计与样本

  • 采用Friedman检验、Spearman相关、Passing-Bablok回归和Bland-Altman分析评估方法间一致性。
  • 以5份混合临床血浆样本为校准材料,用回归方程对CLIA平台进行针对LC-MS/MS的再校准,并比较再校准前后的一致性。

主要发现

  • LC-MS/MS测得的醛固酮中位数为120.75 pg/mL,显著低于6个CLIA平台的129.29至216.25 pg/mL(P < 0.05)。
  • 所有检测方法间相关性很强(R ≥ 0.955),但多数回归斜率偏离1(0.909至1.444),截距范围为-31.424至52.272 pg/mL。
  • Bland-Altman图显示方法间相对平均差异较大(-2.396 %至55.876 %)。
  • 再校准过程显著降低了相对平均差异,但在解决比例偏差和系统偏差方面改善有限。

临床怎么用

  • 临床解读醛固酮结果时应关注检测平台差异,跨平台比较或随访时需注意CLIA与LC-MS/MS间可能存在的系统偏差。
  • 对CLIA平台按LC-MS/MS进行再校准可减小相对平均差异,但仍需警惕残余比例偏差与系统偏差对临床决策的影响。

局限性

  • 再校准后比例偏差和系统偏差改善有限,提示校准策略与检测方法仍需优化。
  • 原文摘要未报告样本量以外的更多局限信息,无法进一步归纳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate aldosterone (ALD) measurement is vital in managing diseases such as primary aldosteronism (PA). However, inter-platform inconsistency across chemiluminescence immunoassay (CLIA) platforms complicates clinical decisions. This study conducted the largest comparison of CLIA platforms (six CLIA platforms) and one liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for ALD detection to date, systematically evaluated inter-platform consistency and explored the role of recalibration strategy based on LC-MS/MS in improving consistency among CLIA platforms. METHODS: Fifty pooled clinical plasma samples were used to evaluate ALD levels across six different CLIA platforms and one LC-MS/MS assay. Friedman's test, Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis were used to evaluate the consistency among assays. In addition, CLIA platforms were recalibrated against LC-MS/MS using regression equations with five pooled clinical plasma samples as calibration materials, and consistency was evaluated before and after recalibration. RESULTS: LC-MS/MS yielded significantly lower ALD levels than six CLIA platforms (median: 120.75 vs. 129.29 to 216.25 pg/mL, P < 0.05). All assays correlated strongly (R ≥ 0.955), yet regression parameters revealed most slopes deviated from 1 (0.909 to 1.444) and intercepts ranged from -31.424 to 52.272 pg/mL. Bland-Altman plots demonstrated large relative mean differences (-2.396 % to 55.876 %) between assays. The recalibration process significantly reduced relative mean differences, whereas it showed limited improvement in addressing both proportional and systematic biases. CONCLUSIONS: These findings demonstrate that the consistency among CLIA platforms and LC-MS/MS assays is suboptimal. Actionable design strategies for developing recalibration coefficients, which reduce relative mean differences, are provided for CLIA platforms, emphasizing the necessity for standardized calibration to reduce inter-platform variability in clinical ALD measurement. The persistent proportional and systematic biases underscore the urgency for optimization in calibration strategy and detection methodology.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Zhang J, Luo B, Fan Z, et al. Liquid chromatography-tandem mass spectrometry-based recalibration reduces inter-platform variability in aldosterone detection across chemiluminescence immunoassay platforms. Clin Chim Acta. 2025. PMID: 41101439. doi:10.1016/j.cca.2025.120604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。